Cite
HARVARD Citation
Jin, P. et al. (n.d.). 105P Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study. Immuno-oncology technology. p. . [Online].